OncLive TV

Corey J. Langer, MD, from the Abramson Cancer Center, discusses the investigation of targeted therapies for patients with locally advanced non-small cell lung cancer.

Nancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.

Michael L. Krychman, MD, Executive Director of the Southern California Center for Sexual Health and Survivorship Medicine, discusses managing and treating sexual health concerns in cancer patients and survivors.

Karen Masino, from Ingalls Memorial Hospital, discusses the intricacies of developing a survivorship program.

Julie R. Gralow, MD, from Seattle Cancer Care Alliance, discusses the side effects associated with the administration of zoledronic acid.

James Mohler, MD, from Roswell Park Cancer Institute, discusses androgen-deprivation therapy, a standard treatment for men with metastatic prostate cancer.

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the phase III EMILIA trial that examined the T-DM1 for women with HER2-positive breast cancer.

Rajni Kannan discusses the importance patient education or managing the side effects associated ipilimumab and vemurafenib in metastatic melanoma.

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the ever changing and evolving world of clinical cancer research.

Daniel P. Petrylak, MD, from the Smilow Cancer Center, discusses the recent approval and future role of enzalutamide for patients with prostate cancer.

Antoni Ribas, MD, from the UCLA Jonsson Comprehensive Cancer Center, discusses a phase I/II trial combining vemurafenib and ipilimumab for metastatic melanoma.

Rebecca S. Sippel, MD, from University of Wisconsin, explains the need for added screening for those at high-risk of developing thyroid cancer.

Dr. Louis Weiner, from Lombardi Comprehensive Cancer Center, on the T-DM1 mechanism of action in HER2-positive breast cancer.

Kathleen M. Foley, MD, from Memorial Sloan-Kettering Cancer Center, on the history and future goals for cancer pain management.

Dr. Eric Sherman, Memorial Sloan-Kettering Cancer Center, on the optimal sequencing of cabozantinib and vandetanib for patients with medullary thyroid cancer.

Agustin A. Garcia, MD, from Keck School of Medicine of USC, discusses clinical trials that investigated combination therapy for treating advanced breast cancer.

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, previews several trials that will likely be presented at the 54th annual ASH meeting.

Pathologist Dr. Elizabeth Hammond, from Intermountain Healthcare, Discusses the Ongoing ASCO/CAP HER2 Testing Guideline Revisions.

Lung cancer survivor, Bonnie Addario, the founder of the Bonnie J. Addario Lung Cancer Foundation, discusses the prevalent stigma that lung cancer is a self-inflicted disease caused solely by smoking.

Carrie Stricker from the Abramson Cancer Center of the University of Pennsylvania on the Efficacy of Survivorship Care Plans for Posttreatment Breast Cancer Survivors.

Dr. David Gandara from the UC Davis Comprehensive Cancer Center on Patient Selection for Molecular Testing in Lung Cancer

Dr. George Demetri, from the Dana-Farber Cancer Institute, Describes the Mechanism of Action of Regorafenib in Gastrointestinal Stromal Tumors.

Dr. Daniel Petrylak, from the Smilow Cancer Center at Yale-New Haven, Explains the Correlation Between Immune Response to Sipuleucel-T and Survival.

Dr. Peter Choyke, from the National Cancer Institute, Molecular Imaging Program, Discusses Current Molecular Imaging Research.

Dr. Howard Burris, from the Sarah Cannon Research Institute, Discusses the mTOR Inhibitor Everolimus for HER2-Negative Breast Cancer.

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, Discusses the Antibody Drug Conjugate T-DM1 for Breast Cancer.

Donna Berry, from the Dana-Farber Cancer Institute, Explains a Nurse-Led Education Program That Enhanced Oral Therapy Compliance.

Dr. Giorgio Scagliotti, from the University of Turin, San Luigi Hospital, on Combining Targeted Therapies With Chemotherapy for Lung Cancer Patients.

Dr. James Mohler, from Roswell Park Cancer Institute, Discusses the Need for Intermediate Endpoints for Early Stage Prostate Cancer Trials.

Dr. Aleksandar Sekulic, from the Mayo Clinic in Arizona, on the Hedgehog Pathway Inhibitor Vismodegib for Basal Cell Carcinoma.